SITC Archive Library

SITC 30th Anniversary Annual Meeting (2015): Coinhibition & Costimulation
November 6-8, 2015
Gaylord National Hotel & Convention Center National Harbor, MD

Session Co-Chairs
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Medical Center
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center  

SITC 30th Anniversary Annual Meeting Organizers
Sandra Demaria, MD – Weill Cornell Medical College
Madhav Dhodapkar, MD – Yale University
Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre
Jennifer A. Wargo, MD – University of Texas MD Anderson Cancer Center
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute

Program Summary
The emergence of agents aimed to modulate the activity of accessory proteins expressed by T cells has shown great therapeutic promise in cancer patients. In particular, blockade of CTLA-4 and PD-1 signaling with Abs have recently been approved for patients with melanoma and lung cancer. This session at the SITC 30th Anniversary Annual Meeting on Saturday, November 7, 2015 in National Harbor, MD explored new pathways known to affect costimulation and coinhibition of T cells, which included OX40 (costimulation) and VISTA (coinhibition). The session also highlighted an immunotherapeutic combination that has shown great promise in a recent clinic trial (anti-CTLA-4/anti-PD-1). This field is in its infancy and as new data and targets emerge it will likely trigger a paradigm shift in the treatment of cancer for years to come.

About the SITC 30th Anniversary Annual Meeting
SITC's 30th Anniversary Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving the outcome for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy research. The meeting consisted of cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for both structured and informal discussions including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as ongoing SITC projects.

Target Audience
The target audience for this program included basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research as well as pharmacists and payers that wished to learn more about cancer immunology and immunotherapy and its incorporation into current (and future) effective cancer treatment.


#2015#AnnualMeeting #ClinicalTrials #HeadandNeckCancers 
#Melanoma #PresentationSlides #SITC #CombinationTherapy #ImmuneCheckpointInhibitors 
#Ipilimumab #Nivolumab #Pembrolizumab #AdverseEvents #Toxicities #Clinician #Industry 
#Oncologist #Researcher​ #Video